22nd Century Net Income 2011-2019 | XXII

22nd Century net income from 2011 to 2019. Net income can be defined as company's net profit or loss after all revenues, income items, and expenses have been accounted for.
22nd Century Annual Net Income
(Millions of US $)
2018 $-8
2017 $-13
2016 $-12
2015 $-11
2014 $-16
2013 $-26
2012 $-7
2011 $-1
2010 $-1
22nd Century Quarterly Net Income
(Millions of US $)
Q1 2019 $-2
Q4 2018 $-9
Q3 2018 $6
Q2 2018 $-7
Q1 2018 $1
Q4 2017 $-4
Q3 2017 $-3
Q2 2017 $-3
Q1 2017 $-3
Q4 2016 $-3
Q3 2016 $-3
Q2 2016 $-3
Q1 2016 $-3
Q4 2015 $-3
Q3 2015 $-3
Q2 2015 $-1
Q1 2015 $-4
Q4 2014 $-6
Q3 2014 $-3
Q2 2014 $-2
Q1 2014 $-5
Q4 2013 $-8
Q3 2013 $-15
Q2 2013 $-0
Q1 2013 $-3
Q4 2012 $-4
Q3 2012 $-0
Q2 2012 $0
Q1 2012 $-2
Q4 2011 $1
Q3 2011 $-0
Q2 2011 $-1
Q1 2011 $-1
Q4 2010 $0
Sector Industry Market Cap Revenue
Consumer Staples Tobacco Products $0.244B $0.026B
22nd Century Group, Inc. is a plant biotechnology company focused on decreasing/increasing the level of nicotine in the tobacco plant through genetic engineering and breeding. The Company is focused on development of smoking cessation aid and owns and controls several patents. The company's products include X-22, a prescription smoking cessation aid, which is a tobacco-based botanical medical product for use as a smoking cessation therapy. 22nd Century Group, Inc. is based in Williamsville, New York.
Stock Name Country Market Cap PE Ratio
Philip Morris (PM) United States $120.108B 14.88
Altria (MO) United States $95.155B 12.91
British American Tobacco (BTI) United Kingdom $77.355B 0.00
Universal (UVV) United States $1.475B 13.18
Vector Group (VGR) United States $1.400B 15.99
Schweitzer-Mauduit (SWM) United States $1.003B 9.72
Turning Point Brands (TPB) United States $0.999B 27.41